Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 26, 2020
Daily News
June 26, 2020
- LDP’s Coronavirus Task Force Calls for Caution in Off-Year Re-Pricing Debate
June 26, 2020
- Keidanren Chief Cited Industry’s Concerns about Off-Year Re-Pricing at CEFP Confab, Minutes Reveal
June 26, 2020
- Japan OK for MSD’s 9-Valent HPV Vaccine Could Be Delayed after Deluge of Comments Hit Proposed Rule Changes
June 26, 2020
- MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis
June 26, 2020
- Eisai’s Parkinson’s Med Equfina Gets South Korea Nod
June 26, 2020
- Sosei, AbbVie Link Arms for Inflammatory and Autoimmune Disease Drugs
June 26, 2020
- Ruling Party Members Mull Govt’s Stronger Control Functions for Infectious Diseases, with Future COVID-19 Measures in Mind
June 26, 2020
- Carna Biosciences Takes Back Kinase Inhibitor from Canadian Licensee
June 26, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…